McCormick Rachel, Goljanek-Whysall Katarzyna
Musculoskeletal Biology II, Centre for Integrated Research into Musculoskeletal Aging, Institute of Aging and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Int Rev Cell Mol Biol. 2017;334:265-308. doi: 10.1016/bs.ircmb.2017.03.005. Epub 2017 Apr 17.
Skeletal muscle is one of the biggest organs of the body with important mechanistic and metabolic functions. Muscle homeostasis is controlled by environmental, genetic, and epigenetic factors. Indeed, MiRNAs, small noncoding RNAs robust regulators of gene expression, have and have been shown to regulate muscle homeostasis on several levels: through controlling myogenesis, muscle growth (hypertrophy) and atrophy, as well as interactions of muscle with other tissues. Given the large number of MiRNA target genes and the important role of MiRNAs in most physiological processes and various diseases, MiRNAs may have an enormous potential as therapeutic targets against numerous disorders, including pathologies of muscle. The purpose of this review is to present the current knowledge of the role of MiRNAs in skeletal muscle homeostasis and pathologies and the potential of MiRNAs as therapeutics for skeletal muscle wasting, with particular focus on the age- and disease-related loss of muscle mass and function.
骨骼肌是人体最大的器官之一,具有重要的机械和代谢功能。肌肉稳态受环境、遗传和表观遗传因素的控制。事实上,微小RNA(MiRNAs)作为基因表达的强大调控因子,是一类小的非编码RNA,已被证明在多个层面上调节肌肉稳态:通过控制肌生成、肌肉生长(肥大)和萎缩,以及肌肉与其他组织的相互作用。鉴于大量的MiRNA靶基因以及MiRNAs在大多数生理过程和各种疾病中的重要作用,MiRNAs作为针对多种疾病(包括肌肉疾病)的治疗靶点可能具有巨大潜力。本综述的目的是介绍目前关于MiRNAs在骨骼肌稳态和疾病中的作用的知识,以及MiRNAs作为治疗骨骼肌萎缩的疗法的潜力,特别关注与年龄和疾病相关的肌肉质量和功能丧失。